Are statins a treatment option for multiple sclerosis?

Hemmer, 2002, New concepts in the immunopathogenesis of multiple sclerosis, Nat Rev Neurosci, 3, 291, 10.1038/nrn784 Neuhaus, 2003, Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection, Trends Pharmacol Sci, 24, 131, 10.1016/S0165-6147(03)00028-2 Polman, 2003, New and emerging treatment options for multiple sclerosis, Lancet Neurol, 2, 563, 10.1016/S1474-4422(03)00505-2 Larosa, 1999, Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials, JAMA, 282, 2340, 10.1001/jama.282.24.2340 Davidson, 2001, Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust, Drugs, 61, 197, 10.2165/00003495-200161020-00005 Black, 1998, An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor, Arch Intern Med, 158, 577, 10.1001/archinte.158.6.577 Gotto, 2003, Safety and statin therapy: reconsidering the risks and benefits, Arch Intern Med, 163, 657, 10.1001/archinte.163.6.657 Cutts, 1989, Role of mevalonic acid in the regulation of natural killer cell cytotoxicity, J Cell Physiol, 139, 550, 10.1002/jcp.1041390314 Kobashigawa, 1995, Effects of pravastatin on outcomes after cardiac transplantation, N Engl J Med, 333, 621, 10.1056/NEJM199509073331003 Kurakata, 1996, Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro, Immunopharmacology, 34, 51, 10.1016/0162-3109(96)00108-7 Weitz-Schmidt, 2002, Statins as anti-inflammatory agents, Trends Pharmacol Sci, 23, 482, 10.1016/S0165-6147(02)02077-1 Baker, 2003, Potential of statins for the treatment of multiple sclerosis, Lancet Neurol, 2, 9, 10.1016/S1474-4422(03)00256-4 Stanislaus, 1999, Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin, Neurosci Lett, 269, 71, 10.1016/S0304-3940(99)00414-0 Youssef, 2002, The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease, Nature, 420, 78, 10.1038/nature01158 Aktas, 2003, Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin, J Exp Med, 197, 725, 10.1084/jem.20021425 Greenwood, 2003, Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis, FASEB J, 17, 905, 10.1096/fj.02-1014fje Nath, 2004, Potential targets of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for multiple sclerosis therapy, J Immunol, 172, 1273, 10.4049/jimmunol.172.2.1273 Neuhaus, 2002, Statins as immunomodulators: comparison with interferon-beta 1b in MS, Neurology, 59, 990, 10.1212/WNL.59.7.990 Sena, 2003, Therapeutic potential of lovastatin in multiple sclerosis, J Neurol, 250, 754, 10.1007/s00415-003-1070-8 Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet (in press). Takemoto, 2001, Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, Arterioscler Thromb Vasc Biol, 21, 1712, 10.1161/hq1101.098486 Singh, 1999, The IL-1 receptor and Rho directly associate to drive cell activation in inflammation, J Clin Invest, 103, 1561, 10.1172/JCI5754 Kwak, 2000, Statins as a newly recognized type of immunomodulator, Nat Med, 6, 1399, 10.1038/82219 Weitz-Schmidt, 2001, Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site, Nat Med, 7, 687, 10.1038/89058 Archelos, 1997, The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications, Mol Med Today, 3, 310, 10.1016/S1357-4310(97)01066-6 Pahan, 1997, Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages, J Clin Invest, 100, 2671, 10.1172/JCI119812 Sakai, 1997, HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density liproprotein, Atherosclerosis, 133, 51, 10.1016/S0021-9150(97)00118-4 Aikawa, 2001, An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases, and tissue factor in vivo, and in vitro, Circulation, 103, 276, 10.1161/01.CIR.103.2.276 Niwa, 1996, Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line, Int J Immunopharmacology, 18, 669, 10.1016/S0192-0561(96)00068-9 Honjo, 2002, Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina, Arch Ophthalmol, 120, 1707, 10.1001/archopht.120.12.1707 Diomede, 2001, In vivo anti-inflammatory effects of statins is mediated by nonsterol mevalonate products, Arterioscler Thromb Vasc Biol, 21, 1327, 10.1161/hq0801.094222 Rudich, 1998, HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation, Transplant Proc, 30, 992, 10.1016/S0041-1345(98)00123-7 Zacco, 2003, 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity, J Neurosci, 23, 11104, 10.1523/JNEUROSCI.23-35-11104.2003 Steinman, 2001, Multiple sclerosis: a two-stage disease, Nat Immunol, 2, 762, 10.1038/ni0901-762